50% off the $29 audit or $99 Fix-It Kit. Use at checkout:
⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
OXLUMO® (lumasiran)
What this score means
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. OXLUMO® (lumasiran) just got measured.
4/10 means OXLUMO® (lumasiran) is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
About OXLUMO® (lumasiran)
OXLUMO® (lumasiran) is the first FDA‐approved medication for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults. See Important Safety Information on risk of injection site reactions.
Key Topics
Details
Industry: Healthcare
oxlumohcp.comAI Visibility Breakdown
1
Structured Data
8
Content Structure
7
Entity Clarity
2
E-E-A-T Signals
6
Technical AEO
2
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Trust Is the Product. AI Is How You Build It at Scale.
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for OXLUMO® (lumasiran).
Source & Attribution
Scored by Engagemii on June 28, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/oxlumohcp
Cite this score: Engagemii (2026). "AEO Score for OXLUMO® (lumasiran)." Retrieved from https://engagemii.com/aeo/brands/oxlumohcp
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform